Skip to content

Enhancement of Emmetropization in Hyperopic Infants

Enhancement of Emmetropization in Hyperopic Infants

Status
Terminated
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00574717
Enrollment
6
Registered
2007-12-17
Start date
2007-12-31
Completion date
2010-09-30
Last updated
2012-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Farsightedness, Hypermetropia, Hyperopia

Keywords

hyperopia, ocular refraction, infant, vision

Brief summary

To determine if wearing a moderate spectacle under-correction (3.00D) and performing activities designed to stimulate accurate accommodation during a 15-month period will enhance emmetropization in highly hyperopic (between +5.00D and +7.00D) 3-month old infants.

Detailed description

The purpose of the project is to determine if emmetropization can be enhanced in very farsighted babies. We will give them glasses with a partial correction, an amount that is less than their full degree of farsightedness but enough to put them in the zone of effective emmetropization. This 'boost' is meant to enable very farsighted babies to use their eyes in a normal way and emmetropize as normal infants. This partial correction would be given at 3 months of age for a period of up to 15 months. A program of visual engagement is also provided in order to encourage the normal development and use of accommodation. As changes in farsightedness occur, the power of the glasses will be reduced at follow up appointments to keep the farsightedness within the zone of effective emmetropization. Once an infant reaches a normal amount of farsightedness, the glasses would be discontinued.

Interventions

PROCEDURESpectacles

Infants will receive spectacles with 3.00D of under-correction relative to the spherical equivalent in each eye as measured by the cycloplegic retinoscopy performed at baseline. They will also receive the full amount of measured astigmatism in their glasses. Changes in spectacle lens power will be made as needed at follow-up visits to keep the level of under-correction within 0.50D of the target 3.00D. A program of visual engagement is also provided to encourage the normal development and use of accommodation. Treatment will continue for 15 months (until 18 months of age) or until the infant reaches a spherical equivalent refractive error of +3.00D or less hyperopia.

Sponsors

The Ohio Lions Eye Research Foundation
CollaboratorUNKNOWN
Ohio State University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
8 Weeks to 20 Weeks
Healthy volunteers
No

Inclusion criteria

* 3 months of age (between 8 weeks and 20 weeks)at the baseline examination * Either gender, any ethnicity * Birthweight greater than 2500g * Normal pregnancy and delivery (including Cesarean section delivery but excluding serious complications or conditions such as eclampsia or rubella) * Hyperopia of +5.00D or more but less than +7.00D spherical equivalent refractive error in each eye by cycloplegic retinoscopy using cyclopentolate 1% * Currently under the care of a pediatrician

Exclusion criteria

* Anisometropia greater than 1.00D (difference in spherical equivalent) * Strabismus * Previous history of difficulty with pupillary dilation * History of cardiac, liver, asthma, or other respiratory disease * History of ocular disease or active ocular inflammation

Design outcomes

Primary

MeasureTime frame
The primary outcome will be to determine if the criterion level for emmetropization (≤+3.00D by 18 months of age) is met and maintained by at least 70% of treated infants.15 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026